Improving Efficacy and Safety of Drugs in Pediatric Population: New Challenges
| Author | : Domenica Altavilla |
| Publisher | : Frontiers Media SA |
| Total Pages | : 183 |
| Release | : 2022-12-01 |
| Genre | : Science |
| ISBN | : 2832508014 |
Improving Efficacy And Safety Of Drugs In Pediatric Population New Challenges
Download Improving Efficacy And Safety Of Drugs In Pediatric Population New Challenges full books in PDF, epub, and Kindle. Read online free Improving Efficacy And Safety Of Drugs In Pediatric Population New Challenges ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Safe and Effective Medicines for Children
| Author | : Institute of Medicine |
| Publisher | : National Academies Press |
| Total Pages | : 432 |
| Release | : 2012-10-13 |
| Genre | : Medical |
| ISBN | : 0309225493 |
The Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) were designed to encourage more pediatric studies of drugs used for children. The FDA asked the IOM to review aspects of pediatric studies and changes in product labeling that resulted from BPCA and PREA and their predecessor policies, as well as assess the incentives for pediatric studies of biologics and the extent to which biologics have been studied in children. The IOM committee concludes that these policies have helped provide clinicians who care for children with better information about the efficacy, safety, and appropriate prescribing of drugs. The IOM suggests that more can be done to increase knowledge about drugs used by children and thereby improve the clinical care, health, and well-being of the nation's children.
Rational Therapeutics for Infants and Children
| Author | : Institute of Medicine |
| Publisher | : National Academies Press |
| Total Pages | : 135 |
| Release | : 2000-04-07 |
| Genre | : Medical |
| ISBN | : 0309183642 |
The Institute of Medicine's (IOM's) Roundtable on Research and Development of Drugs, Biologics, and Medical Devices evolved from the Forum on Drug Development, which was established in 1986. Sponsor representatives and IOM determined the importance of maintaining a neutral setting for discussions regarding long-term and politically sensitive issues justified the need to revise and enhance past efforts. The new Roundtable is intended to be a mechanism by which a broad group of experts from the public* and private sectors can be convened to conduct a dialogue and exchange information related to the development of drugs, biologics, and medical devices. Members have expertise in clinical medicine, pediatrics, clinical pharmacology, health policy, health insurance, industrial management, and product development; and they represent interests that address all facets of public policy issues. From time to time, the Roundtable requests that a workshop be conducted for the purpose of exploring a specific topic in detail and obtaining the views of additional experts. The first workshop for the Roundtable was held on April 14 and 15, 1998, and was entitled Assuring Data Quality and Validity in Clinical Trials for Regulatory Decision Making. The summary on that workshop is available from IOM. This workshop summary covers the second workshop, which was held on May 24 and 25, 1999, and which was aimed at facilitating the development and proper use of drugs, biologics, and medical devices for infants and children. It explores the scientific underpinnings and clinical needs, as well as the regulatory, legal, and ethical issues, raised by this area of research and development.
Guide to Paediatric Drug Development and Clinical Research
| Author | : Klaus Rose |
| Publisher | : Karger Medical and Scientific Publishers |
| Total Pages | : 240 |
| Release | : 2010-01-01 |
| Genre | : Medical |
| ISBN | : 3805593627 |
Children in the developed world have never enjoyed better medical care: mortality has decreased and many fatal diseases of the past can today be prevented or even cured. However, the current practice of pharmacotherapy in children does not reflect existing scientific knowledge and has come under scrutiny by paediatricians, pharmacists and regulatory authorities. In order to advance the development of medicines tailored to paediatric needs, US and EU legislators have taken action, and the WHO has initiated a global paediatric campaign. This book gives an overview over the worldwide activities that increasingly include children in the development of new medicines. Triggered by both a better understanding of how the child's body develops as well as recent legislation in the USA and in Europe, this comprises dosing, ethics, age-appropriate pharmaceutical forms and clinical trials, to name just a few aspects.A wide spectrum of readers will profit from this book, including paediatricians, pharmacists, general practitioners and health care professionals involved in child care and paediatric research, clinical trial personnel, patient advocacy groups, ethics committees, politicians, parents and interested lay persons.
Addressing the Barriers to Pediatric Drug Development
| Author | : Institute of Medicine |
| Publisher | : National Academies Press |
| Total Pages | : 64 |
| Release | : 2008-08-12 |
| Genre | : Medical |
| ISBN | : 0309178657 |
Decades of research have demonstrated that children do not respond to medications in the same way as adults. Differences between children and adults in the overall response to medications are due to profound anatomical, physiological, and developmental differences. Although few would argue that children should receive medications that have not been adequately tested for safety and efficacy, the majority of drugs prescribed for children-50 to 75 percent-have not been tested in pediatric populations. Without adequate data from such testing, prescribing drugs appropriately becomes challenging for clinicians treating children, from infancy through adolescence. Addressing the Barriers to Pediatric Drug Development is the summary of a workshop, held in Washington, D.C. on June 13, 2006, that was organized to identify barriers to the development and testing of drugs for pediatric populations, as well as ways in which the system can be improved to facilitate better treatments for children.
Ethical Conduct of Clinical Research Involving Children
| Author | : Institute of Medicine |
| Publisher | : National Academies Press |
| Total Pages | : 445 |
| Release | : 2004-07-09 |
| Genre | : Medical |
| ISBN | : 0309133386 |
In recent decades, advances in biomedical research have helped save or lengthen the lives of children around the world. With improved therapies, child and adolescent mortality rates have decreased significantly in the last half century. Despite these advances, pediatricians and others argue that children have not shared equally with adults in biomedical advances. Even though we want children to benefit from the dramatic and accelerating rate of progress in medical care that has been fueled by scientific research, we do not want to place children at risk of being harmed by participating in clinical studies. Ethical Conduct of Clinical Research Involving Children considers the necessities and challenges of this type of research and reviews the ethical and legal standards for conducting it. It also considers problems with the interpretation and application of these standards and conduct, concluding that while children should not be excluded from potentially beneficial clinical studies, some research that is ethically permissible for adults is not acceptable for children, who usually do not have the legal capacity or maturity to make informed decisions about research participation. The book looks at the need for appropriate pediatric expertise at all stages of the design, review, and conduct of a research project to effectively implement policies to protect children. It argues persuasively that a robust system for protecting human research participants in general is a necessary foundation for protecting child research participants in particular.
Drug Benefits and Risks
| Author | : Chris J. van Boxtel |
| Publisher | : John Wiley & Sons |
| Total Pages | : 738 |
| Release | : 2001-11-28 |
| Genre | : Medical |
| ISBN | : 9780471899273 |
This is an inclusive reference exploring the scientific basis and practice of drug therapy. The key concept is to look at the balance between the benefits and risks of drugs but in this context also the social impact which drugs have in modern societies is highlighted. Taking an evidence-based approach to the problem, the practice of clinical pharmacology and pharmacotherapy in the developing as well as the developed world is examined. For this purpose the book * Covers general clinical pharmacology, pharmacology of various drug groups and the treatments specific to various diseases * Gives guidance on how doctors should act so that drugs can be used effectively and safely * Encourages the rational use of drugs in society This book brings together a large amount of excellent content that will be invaluable for anyone working within, or associated with, the field of clinical pharmacology and pharmacotherapy - undergraduates, postgraduates, regulatory authorities and the pharmaceutical industry.
The Management of Clinical Trials
| Author | : Hesham Abdeldayem |
| Publisher | : BoD – Books on Demand |
| Total Pages | : 91 |
| Release | : 2018-06-06 |
| Genre | : Medical |
| ISBN | : 1789232384 |
This concise book is addressed to researchers, clinical investigators, as well as practicing physicians and surgeons who are interested in the fields of clinical research and trials. It covers some important topics related to clinical trials including an introduction to clinical trials, some aspects concerning clinical trials in pediatric age group, and the unique aspects of the design of clinical trials on stem cell therapy.
General Considerations for the Clinical Evaluation of Drugs
| Author | : United States. Food and Drug Administration. Bureau of Drugs |
| Publisher | : |
| Total Pages | : 20 |
| Release | : 1977 |
| Genre | : Drugs |
| ISBN | : |
Pediatric Drug Development
| Author | : Andrew E. Mulberg |
| Publisher | : John Wiley & Sons |
| Total Pages | : 782 |
| Release | : 2013-05-20 |
| Genre | : Medical |
| ISBN | : 1118312058 |
Most medicines have never been adequately tested for safety and efficacy in pediatric populations and preterm, infants and children are particularly vulnerable to adverse drug reactions. Pediatric Drug Development: Concepts and Applications, Second Edition, addresses the unique challenges in conducting effective drug research and development in pediatric populations. This new edition covers the legal and ethical issues of consent and assent, the additional legal and safety protections for children, and the appropriate methods of surveillance and assessment for children of varying ages and maturity, particularly for patient reported outcomes. It includes new developments in biomarkers and surrogate endpoints, developmental pharmacology and other novel aspects of global pediatric drug development. It also encompasses the new regulatory initiatives across EU, US and ROW designed to encourage improved access to safe and effective medicines for children globally. From an international team of expert contributors Pediatric Drug Development: Concepts and Applications is the practical guide to all aspects of the research and development of safe and effective medicines for children.
